Global Genetic Testing Market
Global Genetic Testing Market

Genetic Testing Comprehensive Study by Type (Predictive & presymptomatic testing, Diagnostic testing, Carrier testing, Prenatal testing, New born screening), Application (Cancer genetic testing, Prenatal genetic testing, Filling and capping machinery, Pharmacogenomics genetic testing, Predisposition cancer genetic testing), Testing Sample (Saliva, Hair, Blood, Tumors, Others), Technology (Molecular testing, Cytogenetic testing, Biochemical testing), Clinical indication (Alzheimer's disease, Cancer, Cystic fibrosis, Sickle cell Anaemia, Duchenne's muscular dystrophy, Thalassemia, Huntington’s disease, Others), End user (Blood banks, Hospitals, Nursing homes, Specilaity clinics, Laboratories, Others) Players and Region - Global Market Outlook to 2024

Genetic Testing Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Feb 2019 Edition 208 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Genetic Testing Market Overview:
Molecular diagnostics market is growing at a significant rate due to increasing awareness for the same and rising investments in the diagnostic research. The growing number of test to study multiple genes that may help in managing an individual health condition and the Government initiative to spread awareness with respect to the advantages of the procedure is further expected to drive the growth of the Global Genetic testing market. Genetic disorders are the main reason for chronic diseases. Genetic testing provides technologies which are useful for the early detection of genetic disorders and ensures their treatment and prevention. According to the World Health Organization (WHO), the prevalence of all single-gene diseases at birth is approximately 10 per 1,000 births. Prenatal genetic testing is a technique which helps to detect whether the fetus has any genetic disorders. The genetic disorders are caused due to mutations occurring in genes or change in the DNA of a person. Genetic testing is also performed on tumors to diagnose a disease like Cancer and plan the treatment.

Market Drivers
  • Increased application of gene testing in Oncological research
  • The rising prevalence of genetic disorders
  • Technological advancements
  • Increasing demand for personalized medicine.

Market Trend
  • The shift of focus from clinical science to bioinformatics and growing popularity of these techniques, leading to high rate of adoption of genetic testing technology.

Restraints
  • Inaccuracies in results and reimbursement issues
  • High-cost factor and lack of professional expertise in this market may hamper the market growth rate.

Opportunities
  • Genetic tests in conjugation with other genomic technologies helping to predict the risk of an individual to a disease assisting clinicians to select suitable therapeutic interventions. These factors provide opportunities for vendors to grow in pharmaceutical industry.

Challenges
  • Lack of awareness about genetic diseases and testing in several developing regions.


Competitive Landscape:
The market is fragmented by top global key players who are competing with each other based on strategic development, new product launches and strategic alliances and collaborations between big companies such as Vitrolife partners with Illumina on preimplantation genetic testing business in the genetic testing market in countries like EMEA and Americas. The global genetic testing market is very competitive owing to the presence of well-diversified international and regional players.
Some of the key players profiled in the report are Transgenomic, Inc. (United States), GE Healthcare (United States), 23 & Me (United States), Sequenom, Inc. (United States), Abbott Laboratories (United States), Biocartis SA (Switzerland), Illumina Inc. (United States), 454 Life Sciences (United States), Bio-Rad Laboratories (United States), Luminex Corporation (United States), Affymetrix Inc. (United States), Agilent Technologies Inc. (United States), Cephide Inc. (United States), Beckman Coulter Inc. (United States) and Gene Dx LLC (United States). Additionally, following companies can also be profiled that are part of our coverage like Invitae (United States), Pathway Genomics (United States), Counsyl, Inc. (United States), Asper Biotech (Europe), GenePlanet (Europe) and Ambry Genetics (United States). Analyst at AdvanceMarketAnalytics see United States Players to retain maximum share of Global Genetic Testing market by 2024. Considering Market by Testing Sample, the sub-segment i.e. Saliva will boost the Genetic Testing market. Considering Market by Technology, the sub-segment i.e. Molecular testing will boost the Genetic Testing market. Considering Market by Clinical indication, the sub-segment i.e. Alzheimer's disease will boost the Genetic Testing market. Considering Market by End user, the sub-segment i.e. Blood banks will boost the Genetic Testing market.

Market Highlights:
On 30th January 2019, Ambry Genetics Corp. and leading provider of clinical genetic testing announced its collaboration with the Undiagnosed Diseases Network (UDN), a NIH-funded research study dedicated to solve the most challenging medical mysteries using advanced technologies. The goal of this collaboration is to facilitate the transition of those with negative or uncertain test results to UDN’s program hoping to provide answers for patients afflicted with undiagnosed conditions.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Genetic Testing market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Genetic Testing market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Research Laboratories, Government and regulatory bodies, Healthcare providers, Clinicians and Pharmaceutical companies.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Predictive & presymptomatic testing
  • Diagnostic testing
  • Carrier testing
  • Prenatal testing
  • New born screening
By Application
  • Cancer genetic testing
  • Prenatal genetic testing
  • Filling and capping machinery
  • Pharmacogenomics genetic testing
  • Predisposition cancer genetic testing
By Testing Sample
  • Saliva
  • Hair
  • Blood
  • Tumors
  • Others

By Technology
  • Molecular testing
  • Cytogenetic testing
  • Biochemical testing

By Clinical indication
  • Alzheimer's disease
  • Cancer
  • Cystic fibrosis
  • Sickle cell Anaemia
  • Duchenne's muscular dystrophy
  • Thalassemia
  • Huntington’s disease
  • Others

By End user
  • Blood banks
  • Hospitals
  • Nursing homes
  • Specilaity clinics
  • Laboratories
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased application of gene testing in Oncological research
      • 3.2.2. The rising prevalence of genetic disorders
      • 3.2.3. Technological advancements
      • 3.2.4. Increasing demand for personalized medicine.
    • 3.3. Market Challenges
      • 3.3.1. Lack of awareness about genetic diseases and testing in several developing regions.
    • 3.4. Market Trends
      • 3.4.1. The shift of focus from clinical science to bioinformatics and growing popularity of these techniques, leading to high rate of adoption of genetic testing technology.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Genetic Testing, by Type, Application, Testing Sample, Technology, Clinical indication, End user and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Genetic Testing (Value)
      • 5.2.1. Global Genetic Testing by: Type (Value)
        • 5.2.1.1. Predictive & presymptomatic testing
        • 5.2.1.2. Diagnostic testing
        • 5.2.1.3. Carrier testing
        • 5.2.1.4. Prenatal testing
        • 5.2.1.5. New born screening
      • 5.2.2. Global Genetic Testing by: Application (Value)
        • 5.2.2.1. Cancer genetic testing
        • 5.2.2.2. Prenatal genetic testing
        • 5.2.2.3. Filling and capping machinery
        • 5.2.2.4. Pharmacogenomics genetic testing
        • 5.2.2.5. Predisposition cancer genetic testing
      • 5.2.3. Global Genetic Testing by: Testing Sample (Value)
        • 5.2.3.1. Saliva
        • 5.2.3.2. Hair
        • 5.2.3.3. Blood
        • 5.2.3.4. Tumors
        • 5.2.3.5. Others
      • 5.2.4. Global Genetic Testing by: Technology (Value)
        • 5.2.4.1. Molecular testing
        • 5.2.4.2. Cytogenetic testing
        • 5.2.4.3. Biochemical testing
      • 5.2.5. Global Genetic Testing by: Clinical indication (Value)
        • 5.2.5.1. Alzheimer's disease
        • 5.2.5.2. Cancer
        • 5.2.5.3. Cystic fibrosis
        • 5.2.5.4. Sickle cell Anaemia
        • 5.2.5.5. Duchenne's muscular dystrophy
        • 5.2.5.6. Thalassemia
        • 5.2.5.7. Huntington’s disease
        • 5.2.5.8. Others
      • 5.2.6. Global Genetic Testing by: End user (Value)
        • 5.2.6.1. Blood banks
        • 5.2.6.2. Hospitals
        • 5.2.6.3. Nursing homes
        • 5.2.6.4. Specilaity clinics
        • 5.2.6.5. Laboratories
        • 5.2.6.6. Others
      • 5.2.7. Global Genetic Testing Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
  • 6. Genetic Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Transgenomic, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GE Healthcare (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. 23 & Me (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sequenom, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbott Laboratories (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Biocartis SA (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Illumina Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. 454 Life Sciences (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bio-Rad Laboratories (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Luminex Corporation (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Affymetrix Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Agilent Technologies Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Cephide Inc. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Beckman Coulter Inc. (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Gene Dx LLC (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global Genetic Testing Sale, by Type, Application, Testing Sample, Technology, Clinical indication, End user and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Genetic Testing (Value)
      • 7.2.1. Global Genetic Testing by: Type (Value)
        • 7.2.1.1. Predictive & presymptomatic testing
        • 7.2.1.2. Diagnostic testing
        • 7.2.1.3. Carrier testing
        • 7.2.1.4. Prenatal testing
        • 7.2.1.5. New born screening
      • 7.2.2. Global Genetic Testing by: Application (Value)
        • 7.2.2.1. Cancer genetic testing
        • 7.2.2.2. Prenatal genetic testing
        • 7.2.2.3. Filling and capping machinery
        • 7.2.2.4. Pharmacogenomics genetic testing
        • 7.2.2.5. Predisposition cancer genetic testing
      • 7.2.3. Global Genetic Testing by: Testing Sample (Value)
        • 7.2.3.1. Saliva
        • 7.2.3.2. Hair
        • 7.2.3.3. Blood
        • 7.2.3.4. Tumors
        • 7.2.3.5. Others
      • 7.2.4. Global Genetic Testing by: Technology (Value)
        • 7.2.4.1. Molecular testing
        • 7.2.4.2. Cytogenetic testing
        • 7.2.4.3. Biochemical testing
      • 7.2.5. Global Genetic Testing by: Clinical indication (Value)
        • 7.2.5.1. Alzheimer's disease
        • 7.2.5.2. Cancer
        • 7.2.5.3. Cystic fibrosis
        • 7.2.5.4. Sickle cell Anaemia
        • 7.2.5.5. Duchenne's muscular dystrophy
        • 7.2.5.6. Thalassemia
        • 7.2.5.7. Huntington’s disease
        • 7.2.5.8. Others
      • 7.2.6. Global Genetic Testing by: End user (Value)
        • 7.2.6.1. Blood banks
        • 7.2.6.2. Hospitals
        • 7.2.6.3. Nursing homes
        • 7.2.6.4. Specilaity clinics
        • 7.2.6.5. Laboratories
        • 7.2.6.6. Others
      • 7.2.7. Global Genetic Testing Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Genetic Testing: by Type(USD Million)
  • Table 2. Genetic Testing Predictive & presymptomatic testing , by Region USD Million (2013-2018)
  • Table 3. Genetic Testing Diagnostic testing , by Region USD Million (2013-2018)
  • Table 4. Genetic Testing Carrier testing , by Region USD Million (2013-2018)
  • Table 5. Genetic Testing Prenatal testing , by Region USD Million (2013-2018)
  • Table 6. Genetic Testing New born screening , by Region USD Million (2013-2018)
  • Table 7. Genetic Testing: by Application(USD Million)
  • Table 8. Genetic Testing Cancer genetic testing , by Region USD Million (2013-2018)
  • Table 9. Genetic Testing Prenatal genetic testing , by Region USD Million (2013-2018)
  • Table 10. Genetic Testing Filling and capping machinery , by Region USD Million (2013-2018)
  • Table 11. Genetic Testing Pharmacogenomics genetic testing , by Region USD Million (2013-2018)
  • Table 12. Genetic Testing Predisposition cancer genetic testing , by Region USD Million (2013-2018)
  • Table 13. Genetic Testing: by Testing Sample(USD Million)
  • Table 14. Genetic Testing Saliva , by Region USD Million (2013-2018)
  • Table 15. Genetic Testing Hair , by Region USD Million (2013-2018)
  • Table 16. Genetic Testing Blood , by Region USD Million (2013-2018)
  • Table 17. Genetic Testing Tumors , by Region USD Million (2013-2018)
  • Table 18. Genetic Testing Others , by Region USD Million (2013-2018)
  • Table 19. Genetic Testing: by Technology(USD Million)
  • Table 20. Genetic Testing Molecular testing , by Region USD Million (2013-2018)
  • Table 21. Genetic Testing Cytogenetic testing , by Region USD Million (2013-2018)
  • Table 22. Genetic Testing Biochemical testing , by Region USD Million (2013-2018)
  • Table 23. Genetic Testing: by Clinical indication(USD Million)
  • Table 24. Genetic Testing Alzheimer's disease , by Region USD Million (2013-2018)
  • Table 25. Genetic Testing Cancer , by Region USD Million (2013-2018)
  • Table 26. Genetic Testing Cystic fibrosis , by Region USD Million (2013-2018)
  • Table 27. Genetic Testing Sickle cell Anaemia , by Region USD Million (2013-2018)
  • Table 28. Genetic Testing Duchenne's muscular dystrophy , by Region USD Million (2013-2018)
  • Table 29. Genetic Testing Thalassemia , by Region USD Million (2013-2018)
  • Table 30. Genetic Testing Huntington’s disease , by Region USD Million (2013-2018)
  • Table 31. Genetic Testing Others , by Region USD Million (2013-2018)
  • Table 32. Genetic Testing: by End user(USD Million)
  • Table 33. Genetic Testing Blood banks , by Region USD Million (2013-2018)
  • Table 34. Genetic Testing Hospitals , by Region USD Million (2013-2018)
  • Table 35. Genetic Testing Nursing homes , by Region USD Million (2013-2018)
  • Table 36. Genetic Testing Specilaity clinics , by Region USD Million (2013-2018)
  • Table 37. Genetic Testing Laboratories , by Region USD Million (2013-2018)
  • Table 38. Genetic Testing Others , by Region USD Million (2013-2018)
  • Table 39. South America Genetic Testing, by Country USD Million (2013-2018)
  • Table 40. South America Genetic Testing, by Type USD Million (2013-2018)
  • Table 41. South America Genetic Testing, by Application USD Million (2013-2018)
  • Table 42. South America Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 43. South America Genetic Testing, by Technology USD Million (2013-2018)
  • Table 44. South America Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 45. South America Genetic Testing, by End user USD Million (2013-2018)
  • Table 46. Brazil Genetic Testing, by Type USD Million (2013-2018)
  • Table 47. Brazil Genetic Testing, by Application USD Million (2013-2018)
  • Table 48. Brazil Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 49. Brazil Genetic Testing, by Technology USD Million (2013-2018)
  • Table 50. Brazil Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 51. Brazil Genetic Testing, by End user USD Million (2013-2018)
  • Table 52. Argentina Genetic Testing, by Type USD Million (2013-2018)
  • Table 53. Argentina Genetic Testing, by Application USD Million (2013-2018)
  • Table 54. Argentina Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 55. Argentina Genetic Testing, by Technology USD Million (2013-2018)
  • Table 56. Argentina Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 57. Argentina Genetic Testing, by End user USD Million (2013-2018)
  • Table 58. Rest of South America Genetic Testing, by Type USD Million (2013-2018)
  • Table 59. Rest of South America Genetic Testing, by Application USD Million (2013-2018)
  • Table 60. Rest of South America Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 61. Rest of South America Genetic Testing, by Technology USD Million (2013-2018)
  • Table 62. Rest of South America Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 63. Rest of South America Genetic Testing, by End user USD Million (2013-2018)
  • Table 64. Asia Pacific Genetic Testing, by Country USD Million (2013-2018)
  • Table 65. Asia Pacific Genetic Testing, by Type USD Million (2013-2018)
  • Table 66. Asia Pacific Genetic Testing, by Application USD Million (2013-2018)
  • Table 67. Asia Pacific Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 68. Asia Pacific Genetic Testing, by Technology USD Million (2013-2018)
  • Table 69. Asia Pacific Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 70. Asia Pacific Genetic Testing, by End user USD Million (2013-2018)
  • Table 71. China Genetic Testing, by Type USD Million (2013-2018)
  • Table 72. China Genetic Testing, by Application USD Million (2013-2018)
  • Table 73. China Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 74. China Genetic Testing, by Technology USD Million (2013-2018)
  • Table 75. China Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 76. China Genetic Testing, by End user USD Million (2013-2018)
  • Table 77. Japan Genetic Testing, by Type USD Million (2013-2018)
  • Table 78. Japan Genetic Testing, by Application USD Million (2013-2018)
  • Table 79. Japan Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 80. Japan Genetic Testing, by Technology USD Million (2013-2018)
  • Table 81. Japan Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 82. Japan Genetic Testing, by End user USD Million (2013-2018)
  • Table 83. India Genetic Testing, by Type USD Million (2013-2018)
  • Table 84. India Genetic Testing, by Application USD Million (2013-2018)
  • Table 85. India Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 86. India Genetic Testing, by Technology USD Million (2013-2018)
  • Table 87. India Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 88. India Genetic Testing, by End user USD Million (2013-2018)
  • Table 89. South Korea Genetic Testing, by Type USD Million (2013-2018)
  • Table 90. South Korea Genetic Testing, by Application USD Million (2013-2018)
  • Table 91. South Korea Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 92. South Korea Genetic Testing, by Technology USD Million (2013-2018)
  • Table 93. South Korea Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 94. South Korea Genetic Testing, by End user USD Million (2013-2018)
  • Table 95. Taiwan Genetic Testing, by Type USD Million (2013-2018)
  • Table 96. Taiwan Genetic Testing, by Application USD Million (2013-2018)
  • Table 97. Taiwan Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 98. Taiwan Genetic Testing, by Technology USD Million (2013-2018)
  • Table 99. Taiwan Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 100. Taiwan Genetic Testing, by End user USD Million (2013-2018)
  • Table 101. Australia Genetic Testing, by Type USD Million (2013-2018)
  • Table 102. Australia Genetic Testing, by Application USD Million (2013-2018)
  • Table 103. Australia Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 104. Australia Genetic Testing, by Technology USD Million (2013-2018)
  • Table 105. Australia Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 106. Australia Genetic Testing, by End user USD Million (2013-2018)
  • Table 107. Rest of Asia-Pacific Genetic Testing, by Type USD Million (2013-2018)
  • Table 108. Rest of Asia-Pacific Genetic Testing, by Application USD Million (2013-2018)
  • Table 109. Rest of Asia-Pacific Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 110. Rest of Asia-Pacific Genetic Testing, by Technology USD Million (2013-2018)
  • Table 111. Rest of Asia-Pacific Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 112. Rest of Asia-Pacific Genetic Testing, by End user USD Million (2013-2018)
  • Table 113. Europe Genetic Testing, by Country USD Million (2013-2018)
  • Table 114. Europe Genetic Testing, by Type USD Million (2013-2018)
  • Table 115. Europe Genetic Testing, by Application USD Million (2013-2018)
  • Table 116. Europe Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 117. Europe Genetic Testing, by Technology USD Million (2013-2018)
  • Table 118. Europe Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 119. Europe Genetic Testing, by End user USD Million (2013-2018)
  • Table 120. Germany Genetic Testing, by Type USD Million (2013-2018)
  • Table 121. Germany Genetic Testing, by Application USD Million (2013-2018)
  • Table 122. Germany Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 123. Germany Genetic Testing, by Technology USD Million (2013-2018)
  • Table 124. Germany Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 125. Germany Genetic Testing, by End user USD Million (2013-2018)
  • Table 126. France Genetic Testing, by Type USD Million (2013-2018)
  • Table 127. France Genetic Testing, by Application USD Million (2013-2018)
  • Table 128. France Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 129. France Genetic Testing, by Technology USD Million (2013-2018)
  • Table 130. France Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 131. France Genetic Testing, by End user USD Million (2013-2018)
  • Table 132. Italy Genetic Testing, by Type USD Million (2013-2018)
  • Table 133. Italy Genetic Testing, by Application USD Million (2013-2018)
  • Table 134. Italy Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 135. Italy Genetic Testing, by Technology USD Million (2013-2018)
  • Table 136. Italy Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 137. Italy Genetic Testing, by End user USD Million (2013-2018)
  • Table 138. United Kingdom Genetic Testing, by Type USD Million (2013-2018)
  • Table 139. United Kingdom Genetic Testing, by Application USD Million (2013-2018)
  • Table 140. United Kingdom Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 141. United Kingdom Genetic Testing, by Technology USD Million (2013-2018)
  • Table 142. United Kingdom Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 143. United Kingdom Genetic Testing, by End user USD Million (2013-2018)
  • Table 144. Netherlands Genetic Testing, by Type USD Million (2013-2018)
  • Table 145. Netherlands Genetic Testing, by Application USD Million (2013-2018)
  • Table 146. Netherlands Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 147. Netherlands Genetic Testing, by Technology USD Million (2013-2018)
  • Table 148. Netherlands Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 149. Netherlands Genetic Testing, by End user USD Million (2013-2018)
  • Table 150. Rest of Europe Genetic Testing, by Type USD Million (2013-2018)
  • Table 151. Rest of Europe Genetic Testing, by Application USD Million (2013-2018)
  • Table 152. Rest of Europe Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 153. Rest of Europe Genetic Testing, by Technology USD Million (2013-2018)
  • Table 154. Rest of Europe Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 155. Rest of Europe Genetic Testing, by End user USD Million (2013-2018)
  • Table 156. MEA Genetic Testing, by Country USD Million (2013-2018)
  • Table 157. MEA Genetic Testing, by Type USD Million (2013-2018)
  • Table 158. MEA Genetic Testing, by Application USD Million (2013-2018)
  • Table 159. MEA Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 160. MEA Genetic Testing, by Technology USD Million (2013-2018)
  • Table 161. MEA Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 162. MEA Genetic Testing, by End user USD Million (2013-2018)
  • Table 163. Middle East Genetic Testing, by Type USD Million (2013-2018)
  • Table 164. Middle East Genetic Testing, by Application USD Million (2013-2018)
  • Table 165. Middle East Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 166. Middle East Genetic Testing, by Technology USD Million (2013-2018)
  • Table 167. Middle East Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 168. Middle East Genetic Testing, by End user USD Million (2013-2018)
  • Table 169. Africa Genetic Testing, by Type USD Million (2013-2018)
  • Table 170. Africa Genetic Testing, by Application USD Million (2013-2018)
  • Table 171. Africa Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 172. Africa Genetic Testing, by Technology USD Million (2013-2018)
  • Table 173. Africa Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 174. Africa Genetic Testing, by End user USD Million (2013-2018)
  • Table 175. North America Genetic Testing, by Country USD Million (2013-2018)
  • Table 176. North America Genetic Testing, by Type USD Million (2013-2018)
  • Table 177. North America Genetic Testing, by Application USD Million (2013-2018)
  • Table 178. North America Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 179. North America Genetic Testing, by Technology USD Million (2013-2018)
  • Table 180. North America Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 181. North America Genetic Testing, by End user USD Million (2013-2018)
  • Table 182. United States Genetic Testing, by Type USD Million (2013-2018)
  • Table 183. United States Genetic Testing, by Application USD Million (2013-2018)
  • Table 184. United States Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 185. United States Genetic Testing, by Technology USD Million (2013-2018)
  • Table 186. United States Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 187. United States Genetic Testing, by End user USD Million (2013-2018)
  • Table 188. Canada Genetic Testing, by Type USD Million (2013-2018)
  • Table 189. Canada Genetic Testing, by Application USD Million (2013-2018)
  • Table 190. Canada Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 191. Canada Genetic Testing, by Technology USD Million (2013-2018)
  • Table 192. Canada Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 193. Canada Genetic Testing, by End user USD Million (2013-2018)
  • Table 194. Mexico Genetic Testing, by Type USD Million (2013-2018)
  • Table 195. Mexico Genetic Testing, by Application USD Million (2013-2018)
  • Table 196. Mexico Genetic Testing, by Testing Sample USD Million (2013-2018)
  • Table 197. Mexico Genetic Testing, by Technology USD Million (2013-2018)
  • Table 198. Mexico Genetic Testing, by Clinical indication USD Million (2013-2018)
  • Table 199. Mexico Genetic Testing, by End user USD Million (2013-2018)
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Company Basic Information, Sales Area and Its Competitors
  • Table 210. Company Basic Information, Sales Area and Its Competitors
  • Table 211. Company Basic Information, Sales Area and Its Competitors
  • Table 212. Company Basic Information, Sales Area and Its Competitors
  • Table 213. Company Basic Information, Sales Area and Its Competitors
  • Table 214. Company Basic Information, Sales Area and Its Competitors
  • Table 215. Genetic Testing: by Type(USD Million)
  • Table 216. Genetic Testing Predictive & presymptomatic testing , by Region USD Million (2019-2024)
  • Table 217. Genetic Testing Diagnostic testing , by Region USD Million (2019-2024)
  • Table 218. Genetic Testing Carrier testing , by Region USD Million (2019-2024)
  • Table 219. Genetic Testing Prenatal testing , by Region USD Million (2019-2024)
  • Table 220. Genetic Testing New born screening , by Region USD Million (2019-2024)
  • Table 221. Genetic Testing: by Application(USD Million)
  • Table 222. Genetic Testing Cancer genetic testing , by Region USD Million (2019-2024)
  • Table 223. Genetic Testing Prenatal genetic testing , by Region USD Million (2019-2024)
  • Table 224. Genetic Testing Filling and capping machinery , by Region USD Million (2019-2024)
  • Table 225. Genetic Testing Pharmacogenomics genetic testing , by Region USD Million (2019-2024)
  • Table 226. Genetic Testing Predisposition cancer genetic testing , by Region USD Million (2019-2024)
  • Table 227. Genetic Testing: by Testing Sample(USD Million)
  • Table 228. Genetic Testing Saliva , by Region USD Million (2019-2024)
  • Table 229. Genetic Testing Hair , by Region USD Million (2019-2024)
  • Table 230. Genetic Testing Blood , by Region USD Million (2019-2024)
  • Table 231. Genetic Testing Tumors , by Region USD Million (2019-2024)
  • Table 232. Genetic Testing Others , by Region USD Million (2019-2024)
  • Table 233. Genetic Testing: by Technology(USD Million)
  • Table 234. Genetic Testing Molecular testing , by Region USD Million (2019-2024)
  • Table 235. Genetic Testing Cytogenetic testing , by Region USD Million (2019-2024)
  • Table 236. Genetic Testing Biochemical testing , by Region USD Million (2019-2024)
  • Table 237. Genetic Testing: by Clinical indication(USD Million)
  • Table 238. Genetic Testing Alzheimer's disease , by Region USD Million (2019-2024)
  • Table 239. Genetic Testing Cancer , by Region USD Million (2019-2024)
  • Table 240. Genetic Testing Cystic fibrosis , by Region USD Million (2019-2024)
  • Table 241. Genetic Testing Sickle cell Anaemia , by Region USD Million (2019-2024)
  • Table 242. Genetic Testing Duchenne's muscular dystrophy , by Region USD Million (2019-2024)
  • Table 243. Genetic Testing Thalassemia , by Region USD Million (2019-2024)
  • Table 244. Genetic Testing Huntington’s disease , by Region USD Million (2019-2024)
  • Table 245. Genetic Testing Others , by Region USD Million (2019-2024)
  • Table 246. Genetic Testing: by End user(USD Million)
  • Table 247. Genetic Testing Blood banks , by Region USD Million (2019-2024)
  • Table 248. Genetic Testing Hospitals , by Region USD Million (2019-2024)
  • Table 249. Genetic Testing Nursing homes , by Region USD Million (2019-2024)
  • Table 250. Genetic Testing Specilaity clinics , by Region USD Million (2019-2024)
  • Table 251. Genetic Testing Laboratories , by Region USD Million (2019-2024)
  • Table 252. Genetic Testing Others , by Region USD Million (2019-2024)
  • Table 253. South America Genetic Testing, by Country USD Million (2019-2024)
  • Table 254. South America Genetic Testing, by Type USD Million (2019-2024)
  • Table 255. South America Genetic Testing, by Application USD Million (2019-2024)
  • Table 256. South America Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 257. South America Genetic Testing, by Technology USD Million (2019-2024)
  • Table 258. South America Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 259. South America Genetic Testing, by End user USD Million (2019-2024)
  • Table 260. Brazil Genetic Testing, by Type USD Million (2019-2024)
  • Table 261. Brazil Genetic Testing, by Application USD Million (2019-2024)
  • Table 262. Brazil Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 263. Brazil Genetic Testing, by Technology USD Million (2019-2024)
  • Table 264. Brazil Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 265. Brazil Genetic Testing, by End user USD Million (2019-2024)
  • Table 266. Argentina Genetic Testing, by Type USD Million (2019-2024)
  • Table 267. Argentina Genetic Testing, by Application USD Million (2019-2024)
  • Table 268. Argentina Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 269. Argentina Genetic Testing, by Technology USD Million (2019-2024)
  • Table 270. Argentina Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 271. Argentina Genetic Testing, by End user USD Million (2019-2024)
  • Table 272. Rest of South America Genetic Testing, by Type USD Million (2019-2024)
  • Table 273. Rest of South America Genetic Testing, by Application USD Million (2019-2024)
  • Table 274. Rest of South America Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 275. Rest of South America Genetic Testing, by Technology USD Million (2019-2024)
  • Table 276. Rest of South America Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 277. Rest of South America Genetic Testing, by End user USD Million (2019-2024)
  • Table 278. Asia Pacific Genetic Testing, by Country USD Million (2019-2024)
  • Table 279. Asia Pacific Genetic Testing, by Type USD Million (2019-2024)
  • Table 280. Asia Pacific Genetic Testing, by Application USD Million (2019-2024)
  • Table 281. Asia Pacific Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 282. Asia Pacific Genetic Testing, by Technology USD Million (2019-2024)
  • Table 283. Asia Pacific Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 284. Asia Pacific Genetic Testing, by End user USD Million (2019-2024)
  • Table 285. China Genetic Testing, by Type USD Million (2019-2024)
  • Table 286. China Genetic Testing, by Application USD Million (2019-2024)
  • Table 287. China Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 288. China Genetic Testing, by Technology USD Million (2019-2024)
  • Table 289. China Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 290. China Genetic Testing, by End user USD Million (2019-2024)
  • Table 291. Japan Genetic Testing, by Type USD Million (2019-2024)
  • Table 292. Japan Genetic Testing, by Application USD Million (2019-2024)
  • Table 293. Japan Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 294. Japan Genetic Testing, by Technology USD Million (2019-2024)
  • Table 295. Japan Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 296. Japan Genetic Testing, by End user USD Million (2019-2024)
  • Table 297. India Genetic Testing, by Type USD Million (2019-2024)
  • Table 298. India Genetic Testing, by Application USD Million (2019-2024)
  • Table 299. India Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 300. India Genetic Testing, by Technology USD Million (2019-2024)
  • Table 301. India Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 302. India Genetic Testing, by End user USD Million (2019-2024)
  • Table 303. South Korea Genetic Testing, by Type USD Million (2019-2024)
  • Table 304. South Korea Genetic Testing, by Application USD Million (2019-2024)
  • Table 305. South Korea Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 306. South Korea Genetic Testing, by Technology USD Million (2019-2024)
  • Table 307. South Korea Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 308. South Korea Genetic Testing, by End user USD Million (2019-2024)
  • Table 309. Taiwan Genetic Testing, by Type USD Million (2019-2024)
  • Table 310. Taiwan Genetic Testing, by Application USD Million (2019-2024)
  • Table 311. Taiwan Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 312. Taiwan Genetic Testing, by Technology USD Million (2019-2024)
  • Table 313. Taiwan Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 314. Taiwan Genetic Testing, by End user USD Million (2019-2024)
  • Table 315. Australia Genetic Testing, by Type USD Million (2019-2024)
  • Table 316. Australia Genetic Testing, by Application USD Million (2019-2024)
  • Table 317. Australia Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 318. Australia Genetic Testing, by Technology USD Million (2019-2024)
  • Table 319. Australia Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 320. Australia Genetic Testing, by End user USD Million (2019-2024)
  • Table 321. Rest of Asia-Pacific Genetic Testing, by Type USD Million (2019-2024)
  • Table 322. Rest of Asia-Pacific Genetic Testing, by Application USD Million (2019-2024)
  • Table 323. Rest of Asia-Pacific Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 324. Rest of Asia-Pacific Genetic Testing, by Technology USD Million (2019-2024)
  • Table 325. Rest of Asia-Pacific Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 326. Rest of Asia-Pacific Genetic Testing, by End user USD Million (2019-2024)
  • Table 327. Europe Genetic Testing, by Country USD Million (2019-2024)
  • Table 328. Europe Genetic Testing, by Type USD Million (2019-2024)
  • Table 329. Europe Genetic Testing, by Application USD Million (2019-2024)
  • Table 330. Europe Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 331. Europe Genetic Testing, by Technology USD Million (2019-2024)
  • Table 332. Europe Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 333. Europe Genetic Testing, by End user USD Million (2019-2024)
  • Table 334. Germany Genetic Testing, by Type USD Million (2019-2024)
  • Table 335. Germany Genetic Testing, by Application USD Million (2019-2024)
  • Table 336. Germany Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 337. Germany Genetic Testing, by Technology USD Million (2019-2024)
  • Table 338. Germany Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 339. Germany Genetic Testing, by End user USD Million (2019-2024)
  • Table 340. France Genetic Testing, by Type USD Million (2019-2024)
  • Table 341. France Genetic Testing, by Application USD Million (2019-2024)
  • Table 342. France Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 343. France Genetic Testing, by Technology USD Million (2019-2024)
  • Table 344. France Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 345. France Genetic Testing, by End user USD Million (2019-2024)
  • Table 346. Italy Genetic Testing, by Type USD Million (2019-2024)
  • Table 347. Italy Genetic Testing, by Application USD Million (2019-2024)
  • Table 348. Italy Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 349. Italy Genetic Testing, by Technology USD Million (2019-2024)
  • Table 350. Italy Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 351. Italy Genetic Testing, by End user USD Million (2019-2024)
  • Table 352. United Kingdom Genetic Testing, by Type USD Million (2019-2024)
  • Table 353. United Kingdom Genetic Testing, by Application USD Million (2019-2024)
  • Table 354. United Kingdom Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 355. United Kingdom Genetic Testing, by Technology USD Million (2019-2024)
  • Table 356. United Kingdom Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 357. United Kingdom Genetic Testing, by End user USD Million (2019-2024)
  • Table 358. Netherlands Genetic Testing, by Type USD Million (2019-2024)
  • Table 359. Netherlands Genetic Testing, by Application USD Million (2019-2024)
  • Table 360. Netherlands Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 361. Netherlands Genetic Testing, by Technology USD Million (2019-2024)
  • Table 362. Netherlands Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 363. Netherlands Genetic Testing, by End user USD Million (2019-2024)
  • Table 364. Rest of Europe Genetic Testing, by Type USD Million (2019-2024)
  • Table 365. Rest of Europe Genetic Testing, by Application USD Million (2019-2024)
  • Table 366. Rest of Europe Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 367. Rest of Europe Genetic Testing, by Technology USD Million (2019-2024)
  • Table 368. Rest of Europe Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 369. Rest of Europe Genetic Testing, by End user USD Million (2019-2024)
  • Table 370. MEA Genetic Testing, by Country USD Million (2019-2024)
  • Table 371. MEA Genetic Testing, by Type USD Million (2019-2024)
  • Table 372. MEA Genetic Testing, by Application USD Million (2019-2024)
  • Table 373. MEA Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 374. MEA Genetic Testing, by Technology USD Million (2019-2024)
  • Table 375. MEA Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 376. MEA Genetic Testing, by End user USD Million (2019-2024)
  • Table 377. Middle East Genetic Testing, by Type USD Million (2019-2024)
  • Table 378. Middle East Genetic Testing, by Application USD Million (2019-2024)
  • Table 379. Middle East Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 380. Middle East Genetic Testing, by Technology USD Million (2019-2024)
  • Table 381. Middle East Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 382. Middle East Genetic Testing, by End user USD Million (2019-2024)
  • Table 383. Africa Genetic Testing, by Type USD Million (2019-2024)
  • Table 384. Africa Genetic Testing, by Application USD Million (2019-2024)
  • Table 385. Africa Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 386. Africa Genetic Testing, by Technology USD Million (2019-2024)
  • Table 387. Africa Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 388. Africa Genetic Testing, by End user USD Million (2019-2024)
  • Table 389. North America Genetic Testing, by Country USD Million (2019-2024)
  • Table 390. North America Genetic Testing, by Type USD Million (2019-2024)
  • Table 391. North America Genetic Testing, by Application USD Million (2019-2024)
  • Table 392. North America Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 393. North America Genetic Testing, by Technology USD Million (2019-2024)
  • Table 394. North America Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 395. North America Genetic Testing, by End user USD Million (2019-2024)
  • Table 396. United States Genetic Testing, by Type USD Million (2019-2024)
  • Table 397. United States Genetic Testing, by Application USD Million (2019-2024)
  • Table 398. United States Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 399. United States Genetic Testing, by Technology USD Million (2019-2024)
  • Table 400. United States Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 401. United States Genetic Testing, by End user USD Million (2019-2024)
  • Table 402. Canada Genetic Testing, by Type USD Million (2019-2024)
  • Table 403. Canada Genetic Testing, by Application USD Million (2019-2024)
  • Table 404. Canada Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 405. Canada Genetic Testing, by Technology USD Million (2019-2024)
  • Table 406. Canada Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 407. Canada Genetic Testing, by End user USD Million (2019-2024)
  • Table 408. Mexico Genetic Testing, by Type USD Million (2019-2024)
  • Table 409. Mexico Genetic Testing, by Application USD Million (2019-2024)
  • Table 410. Mexico Genetic Testing, by Testing Sample USD Million (2019-2024)
  • Table 411. Mexico Genetic Testing, by Technology USD Million (2019-2024)
  • Table 412. Mexico Genetic Testing, by Clinical indication USD Million (2019-2024)
  • Table 413. Mexico Genetic Testing, by End user USD Million (2019-2024)
  • Table 414. Research Programs/Design for This Report
  • Table 415. Key Data Information from Secondary Sources
  • Table 416. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Genetic Testing: by Type USD Million (2013-2018)
  • Figure 5. Global Genetic Testing: by Application USD Million (2013-2018)
  • Figure 6. Global Genetic Testing: by Testing Sample USD Million (2013-2018)
  • Figure 7. Global Genetic Testing: by Technology USD Million (2013-2018)
  • Figure 8. Global Genetic Testing: by Clinical indication USD Million (2013-2018)
  • Figure 9. Global Genetic Testing: by End user USD Million (2013-2018)
  • Figure 10. South America Genetic Testing Share (%), by Country
  • Figure 11. Asia Pacific Genetic Testing Share (%), by Country
  • Figure 12. Europe Genetic Testing Share (%), by Country
  • Figure 13. MEA Genetic Testing Share (%), by Country
  • Figure 14. North America Genetic Testing Share (%), by Country
  • Figure 15. Global Genetic Testing share by Players 2018 (%)
  • Figure 16. Global Genetic Testing share by Players (Top 3) 2018(%)
  • Figure 17. Global Genetic Testing share by Players (Top 5) 2018(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Transgenomic, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Transgenomic, Inc. (United States) Revenue: by Geography 2018
  • Figure 21. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 22. GE Healthcare (United States) Revenue: by Geography 2018
  • Figure 23. 23 & Me (United States) Revenue, Net Income and Gross profit
  • Figure 24. 23 & Me (United States) Revenue: by Geography 2018
  • Figure 25. Sequenom, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Sequenom, Inc. (United States) Revenue: by Geography 2018
  • Figure 27. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 28. Abbott Laboratories (United States) Revenue: by Geography 2018
  • Figure 29. Biocartis SA (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Biocartis SA (Switzerland) Revenue: by Geography 2018
  • Figure 31. Illumina Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Illumina Inc. (United States) Revenue: by Geography 2018
  • Figure 33. 454 Life Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 34. 454 Life Sciences (United States) Revenue: by Geography 2018
  • Figure 35. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 36. Bio-Rad Laboratories (United States) Revenue: by Geography 2018
  • Figure 37. Luminex Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 38. Luminex Corporation (United States) Revenue: by Geography 2018
  • Figure 39. Affymetrix Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Affymetrix Inc. (United States) Revenue: by Geography 2018
  • Figure 41. Agilent Technologies Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Agilent Technologies Inc. (United States) Revenue: by Geography 2018
  • Figure 43. Cephide Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Cephide Inc. (United States) Revenue: by Geography 2018
  • Figure 45. Beckman Coulter Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 46. Beckman Coulter Inc. (United States) Revenue: by Geography 2018
  • Figure 47. Gene Dx LLC (United States) Revenue, Net Income and Gross profit
  • Figure 48. Gene Dx LLC (United States) Revenue: by Geography 2018
  • Figure 49. Global Genetic Testing: by Type USD Million (2013-2018)
  • Figure 50. Global Genetic Testing: by Application USD Million (2013-2018)
  • Figure 51. Global Genetic Testing: by Testing Sample USD Million (2013-2018)
  • Figure 52. Global Genetic Testing: by Technology USD Million (2013-2018)
  • Figure 53. Global Genetic Testing: by Clinical indication USD Million (2013-2018)
  • Figure 54. Global Genetic Testing: by End user USD Million (2013-2018)
  • Figure 55. South America Genetic Testing Share (%), by Country
  • Figure 56. Asia Pacific Genetic Testing Share (%), by Country
  • Figure 57. Europe Genetic Testing Share (%), by Country
  • Figure 58. MEA Genetic Testing Share (%), by Country
  • Figure 59. North America Genetic Testing Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Transgenomic, Inc. (United States)
  • GE Healthcare (United States)
  • 23 & Me (United States)
  • Sequenom, Inc. (United States)
  • Abbott Laboratories (United States)
  • Biocartis SA (Switzerland)
  • Illumina Inc. (United States)
  • 454 Life Sciences (United States)
  • Bio-Rad Laboratories (United States)
  • Luminex Corporation (United States)
  • Affymetrix Inc. (United States)
  • Agilent Technologies Inc. (United States)
  • Cephide Inc. (United States)
  • Beckman Coulter Inc. (United States)
  • Gene Dx LLC (United States)
Additional players considered in the study are as follows:
Invitae (United States) , Pathway Genomics (United States) , Counsyl, Inc. (United States) , Asper Biotech (Europe) , GenePlanet (Europe) , Ambry Genetics (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation